Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
[What you need to know about the Moderna and Pfizer coronavirus vaccines] Researchers in the United States set an audacious goal in January last year to develop a coronavirus vaccine within 12 to ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
Now the nation’s top health official, Kennedy is reevaluating the US Health and Human Services’s contract with Moderna, which ...
1h
Times-Herald on MSNFive years later: When Solano County (and the world) went quietSolano County issued a countywide Shelter at Home Health Order and Directive to continue protecting the health and safety of ...
The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results